Article

Identification of small-molecule inhibitors of the A beta-ABAD interaction

Department of Medicine, Columbia University, New York, NY 10032, USA.
Bioorganic & Medicinal Chemistry Letters (Impact Factor: 2.33). 10/2006; 16(17):4657-60. DOI: 10.1016/j.bmcl.2006.05.099
Source: PubMed

ABSTRACT The interaction of amyloid beta peptide (A beta) and A beta-binding alcohol dehydrogenase (ABAD) was recently implicated in the pathogenesis of Alzheimer's disease (AD). Using an ELISA-based screening assay, we identified frentizole, an FDA-approved immunosuppressive drug, as a novel inhibitor of the A beta-ABAD interaction. Analysis of the frentizole structure-activity relationship led to identification of a novel benzothiazole urea with a 30-fold improvement in potency. (c) 2006 Elsevier Ltd. All rights reserved.

0 Followers
 · 
155 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: As an important molecule in the pathogenesis of Alzheimer's disease (AD), amyloid-beta (Abeta) interferes with multiple aspects of mitochondrial function, including energy metabolism failure, production of reactive oxygen species (ROS) and permeability transition pore formation. Recent studies have demonstrated that Abeta progressively accumulates within mitochondrial matrix, providing a direct link to mitochondrial toxicity. Abeta-binding alcohol dehydrogenase (ABAD) is localized to the mitochondrial matrix and binds to mitochondrial Abeta. Interaction of ABAD with Abeta exaggerates Abeta-mediated mitochondrial and neuronal perturbation, leading to impaired synaptic function, and dysfunctional spatial learning/memory. Thus, blockade of ABAD/Abeta interaction may be a potential therapeutic strategy for AD.
    Journal of Alzheimer's disease: JAD 10/2007; 12(2):177-84. · 3.61 Impact Factor
  • Source
    Journal of Combinatorial Chemistry 11/2007; 9(6):855-902. DOI:10.1021/cc700111e · 4.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic dysfunction is one of the early features in Alzheimer's disease (AD) affected brain. Amyloid-beta peptide (Abeta), a major peptide deposited in neuritic plaques, has been considered as an important initiating molecule in the pathogenesis of AD. However, the pathogenic role of Abeta remains to be determined. Here, we review current studies showing that progressive accumulation of Abeta occurs within the mitochondria of both transgenic mice overexpressing mutant Abeta peptide precursor protein and autopsied brains from AD patients. Interaction of Abeta with Abeta-binding alcohol dehydrogenase (ABAD), a short-chain alcohol dehydrogenase in the mitochondrial matrix, leads to mitochondrial dysfunction evidenced by increased reactive oxygen species generation, mitochondrial membrane permeability formation and caspase-3-like activity induction, and decreased activities of the Krebs cycle. These effects can be blocked by intracellular transduction of the ABAD decoy peptide. We hypothesize that Abeta-induced and mitochondria-dependent cytotoxic pathways might play an important role in AD pathogenesis and could be a potential therapeutic target.
    Expert Review of Neurotherapeutics 12/2007; 7(11):1517-25. DOI:10.1586/14737175.7.11.1517 · 2.83 Impact Factor
Show more